MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Multivariable Model to Predict an ACTH Stimulation Test to Diagnose Adrenal Insufficiency Using Previous Test Results.
Lawrence NR. et al, (2023), J Endocr Soc, 7
Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
Gómez C. et al, (2023), Br J Pharmacol
Long-term health consequences of congenital adrenal hyperplasia.
Pofi R. et al, (2023), Clin Endocrinol (Oxf)
Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.
Pofi R. et al, (2023), Endocr Connect, 12
Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine.
Jayasena CN. et al, (2023), Clin Endocrinol (Oxf)